BR0208656A - Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides - Google Patents

Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides

Info

Publication number
BR0208656A
BR0208656A BR0208656-5A BR0208656A BR0208656A BR 0208656 A BR0208656 A BR 0208656A BR 0208656 A BR0208656 A BR 0208656A BR 0208656 A BR0208656 A BR 0208656A
Authority
BR
Brazil
Prior art keywords
steroid resistant
resistant patients
steroid
ligand molecules
patient
Prior art date
Application number
BR0208656-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen David Hearing
Colin Mark Dayan
Michael Roden Norman
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27256143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0208656(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0108817A external-priority patent/GB0108817D0/en
Priority claimed from GB0108821A external-priority patent/GB0108821D0/en
Priority claimed from GB0108816A external-priority patent/GB0108816D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of BR0208656A publication Critical patent/BR0208656A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
BR0208656-5A 2001-04-06 2002-04-05 Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides BR0208656A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0108817A GB0108817D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108821A GB0108821D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108816A GB0108816D0 (en) 2001-04-06 2001-04-06 Therapy
PCT/EP2002/003808 WO2002081508A2 (en) 2001-04-06 2002-04-05 Use of cd25 binding molecules in steroid-resistant patients

Publications (1)

Publication Number Publication Date
BR0208656A true BR0208656A (pt) 2004-08-10

Family

ID=27256143

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208656-5A BR0208656A (pt) 2001-04-06 2002-04-05 Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides

Country Status (21)

Country Link
US (2) US20040146508A1 (https=)
EP (2) EP2058332A1 (https=)
JP (2) JP2005502593A (https=)
KR (2) KR100975042B1 (https=)
CN (1) CN1296386C (https=)
AT (1) ATE408629T1 (https=)
AU (1) AU2002315271B2 (https=)
BR (1) BR0208656A (https=)
CA (1) CA2443405A1 (https=)
CZ (1) CZ20032672A3 (https=)
DE (1) DE60228945D1 (https=)
ES (1) ES2314067T3 (https=)
HU (1) HUP0400986A3 (https=)
IL (2) IL158060A0 (https=)
MX (1) MXPA03009115A (https=)
NO (1) NO20034453L (https=)
NZ (1) NZ528411A (https=)
PL (1) PL363029A1 (https=)
PT (1) PT1379557E (https=)
SK (1) SK12212003A3 (https=)
WO (1) WO2002081508A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
WO2005030252A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2617583A1 (en) * 2005-08-02 2007-02-08 Centenary Institute Of Cancer Medicine And Cell Biology Method for identifying regulatory t cells
WO2009145831A1 (en) * 2008-04-02 2009-12-03 Geisinger Clinic Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab
TW201834698A (zh) * 2017-03-03 2018-10-01 國立研究開發法人國立癌症研究中心 抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5567590A (en) * 1994-01-06 1996-10-22 National Jewish Center For Immunology And Respiratory Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2002081508A2 (en) 2002-10-17
KR100975042B1 (ko) 2010-08-11
IL158060A (en) 2009-12-24
DE60228945D1 (de) 2008-10-30
HUP0400986A2 (hu) 2004-08-30
KR20080110687A (ko) 2008-12-18
NO20034453L (no) 2003-12-04
US20040146508A1 (en) 2004-07-29
US20090274691A1 (en) 2009-11-05
NZ528411A (en) 2005-04-29
NO20034453D0 (no) 2003-10-03
JP2005502593A (ja) 2005-01-27
CA2443405A1 (en) 2002-10-17
JP2009102367A (ja) 2009-05-14
MXPA03009115A (es) 2004-11-22
SK12212003A3 (sk) 2004-05-04
CN1527840A (zh) 2004-09-08
IL158060A0 (en) 2004-03-28
CN1296386C (zh) 2007-01-24
AU2002315271B2 (en) 2006-08-03
ATE408629T1 (de) 2008-10-15
PL363029A1 (en) 2004-11-15
ES2314067T3 (es) 2009-03-16
EP2058332A1 (en) 2009-05-13
HUP0400986A3 (en) 2012-09-28
CZ20032672A3 (cs) 2003-12-17
PT1379557E (pt) 2008-12-29
WO2002081508A3 (en) 2003-08-28
EP1379557B1 (en) 2008-09-17
EP1379557A2 (en) 2004-01-14
KR20030088485A (ko) 2003-11-19

Similar Documents

Publication Publication Date Title
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
HRP20050089A2 (en) Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
BR9908610A (pt) Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
EP0711173A4 (en) INSULATED PEPTIDES THAT MAKE 10 COMPLEXES WITH MHC MULEKÜL HLA-C-KLON AND THEIR USE
DE69633664D1 (de) Genetische marker für brust und eierstockkrebs
DE60217324D1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
PT1272515E (pt) Imunorregulador
DE69834330D1 (de) Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
HUP0102549A2 (hu) Platinakomplex, a komplexek előállítása és gyógyászati alkalmazása
BR0208656A (pt) Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
WO2005035794A3 (en) Detection of prrsv
US5384314B1 (en) 1alpha-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol
KR940021064A (ko) 프레그네인 유도체의 사용 방법
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
PT977716E (pt) Utilizacao de alcoois como aditivos para rebocos e/ou argamassas
BRPI0416843A8 (pt) dímeros de triazina, composição compreendendo os mesmos, seus usos e processos de remoção e purificação de anticorpos
BR0111844A (pt) Uso de um agente acoplador, composições de elastÈmeros, processo de preparação de ditas composições e artigos
BR0303867A (pt) Composições cosméticas, processos de tratamento das matérias queratìnicas e kits de tratamento das matérias queratìnicas
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
MXPA02010813A (es) Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.
Klockars Solvents and the liver

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]